EssityESSITY B
ESSITY B logo
Fair Value
SEK 271.6
Share price29 Jul
SEK 280.63.3% overvalued intrinsic discount
Loading
1Y14.53%
7D1.23%

Analysts Cite Trough Valuation and Limited Catalysts as Essity Price Targets Edge Lower

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
07 Nov 24
Updated
29 Jul 26
Views
221
Not Invested

Last Update 29 Jul 26

Fair value Increased 2.46%

ESSITY B: Cost Pressures And Tissue Review Will Shape Future Returns

Essity's analyst price target has shifted from SEK 265.07 to SEK 271.60. Analysts point to updated fair value estimates and revised assumptions around revenue growth, profit margins and future P/E as key drivers behind the change.

What’s in the News for Essity

  • Essity reported net sales of SEK 35.1b in Q2 2026 with organic growth of 0.3%, driven by higher volumes, while lower price and mix effects influenced overall sales, according to recent H1 2026 results.
  • EBITA excluding items affecting comparability was SEK 4.7b in the period, and the adjusted EBITA margin was 13.4%. The company described this as resilience in profitability during a period of inflationary and cost pressures. Source: Essity H1 2026 report.
  • Management highlighted ongoing price increases, along with investment in AI and product development, as current priorities to support future growth initiatives. Source: Essity H1 2026 report.
  • Essity completed a SEK 3b share buyback program, citing confidence in its balance sheet and a maintained net debt to EBITDA ratio. Source: Essity H1 2026 report.
  • The Board has initiated a review of the Consumer Tissue business area to consider different ownership alternatives. The review may lead to separation, although no decision has been made, and is intended to support optimization of Essity’s product portfolio and value creation according to company statements.

Valuation Changes for Essity

  • Fair Value has risen slightly from SEK 265.07 to SEK 271.60 based on updated analyst assumptions.
  • Discount Rate is unchanged at 5.344%, indicating no adjustment to the assessed risk profile used in the valuation model.
  • Revenue Growth has been revised modestly higher from 2.67% to 2.80%, reflecting updated SEK sales assumptions for Essity.
  • Net Profit Margin has been adjusted slightly from 9.70% to 9.74%, indicating a small change in expected SEK earnings relative to revenue.
  • Future P/E has edged slightly lower from 14.13x to 14.09x, suggesting a marginally different view on Essity’s valuation multiple.
0 viewsusers have viewed this narrative update

Key Takeaways

  • Strong demand in incontinence, medical, and feminine care products, coupled with innovation and brand investments, supports sustained revenue and margin growth globally.
  • Focus on sustainability, premiumization, and ongoing cost-efficiency efforts positions Essity to benefit from changing consumer preferences and improved operating leverage.
  • Structural volume and margin pressures across key segments, rising costs, and increased competition threaten Essity's growth, profitability, and pricing power in core and emerging markets.

Catalysts

About Essity
    Develops, produces, and sells hygiene and health products and services in Europe, North and Latin America, Asia, and internationally.
What are the underlying business or industry changes driving this perspective?
  • The company continues to benefit from high and growing demand in incontinence and medical products, supported by an aging global population, which is driving stable long-term volume and revenue growth in these strategic categories.
  • Essity is experiencing strong growth in Feminine Care and Incontinence Retail segments across multiple geographies, leveraging rising healthcare standards and expanding middle class in emerging markets, supporting expectations of international revenue expansion.
  • Innovations in premium, eco-friendly, and coreless products-along with industry recognition for sustainability-position Essity to capitalize on shifting consumer preference for sustainable and higher-value tissue and hygiene products, which supports both topline growth and margin expansion.
  • Investment in brand building and marketing, as demonstrated by recent awards and increased A&P spend, is expected to drive greater brand loyalty and premiumization, bolstering future sales and improving net margins.
  • Ongoing cost-efficiency initiatives (supply chain savings, planned SG&A reductions, digitalization) are set to enhance operating leverage and protect net margins, especially as the company aims to return to higher volume growth in the face of stabilized input costs.
Essity Earnings and Revenue Growth

Essity Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming Essity's revenue will grow by 2.8% annually over the next 3 years.
  • Analysts assume that profit margins will increase from 8.8% today to 9.7% in 3 years time.
  • Analysts expect earnings to reach SEK 14.6 billion (and earnings per share of SEK 21.52) by about July 2029, up from SEK 12.1 billion today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as SEK16.1 billion.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 14.1x on those 2029 earnings, down from 15.7x today. This future PE is lower than the current PE for the GB Household Products industry at 22.6x.
  • Analysts expect the number of shares outstanding to decline by 1.62% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 5.34%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • Persistent weak volume growth in key segments, particularly in Health & Medical and Baby Care, combined with limited ability to stimulate volumes in a challenging macroeconomic environment, poses a risk of structurally lower revenue growth than anticipated.
  • Rising SG&A costs, notably personnel and IT expenses, paired with insufficient volume growth to absorb these increases, have led to margin contraction and may continue to pressure net margins if costs are not adequately controlled.
  • Ongoing high promotional pressure and aggressive price competition, especially in segments like Baby Care and lower/mid-tier Consumer Tissue, may erode Essity's pricing power and gross margins, particularly if private label and low-cost competitors continue gaining share.
  • Sustained weakness in Professional Hygiene, exacerbated by structural shifts such as reduced restaurant and hotel traffic in North America and Europe, suggests lasting lower demand for away-from-home products, potentially limiting revenue and operating leverage in that segment.
  • Exposure to input cost volatility-including raw materials, tariffs (notably on U.S.-to-Canada exports), and distribution expenses-without commensurate ability to fully pass through these costs in all geographies and segments, could constrain earnings and net margin expansion, especially as industry consolidation intensifies pressure from retailers and distributors.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of SEK271.6 for Essity based on their expectations of its future earnings growth, profit margins and other risk factors.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of SEK310.0, and the most bearish reporting a price target of just SEK215.0.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be SEK149.5 billion, earnings will come to SEK14.6 billion, and it would be trading on a PE ratio of 14.1x, assuming you use a discount rate of 5.3%.
  • Given the current share price of SEK280.6, the analyst price target of SEK271.6 is 3.3% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Essity?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

Fair Value vs Share Price

SEK 271.6
vs SEK 280.63.3% overvalued intrinsic discount
PastFuture0149b2015201820212024202620272029Revenue SEK 149.5bEarnings SEK 14.6b
2.8%
Revenue growth
9.7%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Essity

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Flawless balance sheet and undervalued.

Market capSEK 190.2b
PB2.1x
Estimated Growth2.9%
Dividend Yield3.1%
Full analysis

CEO & management

Ulrika Kolsrud
CEO
2.9yrs
CEO Tenure

Develops, produces, and sells hygiene and health products and services in Europe, North and Latin America, Asia, and internationally.